1. A pharmaceutical formulation comprising: (a) anti-c-met, wherein the antibody against c-met comprises HVR-L1, containing the sequence KSSQSLLYTSSQKNYLA (SEQ ID №1), HVR-L2, comprising the sequence WASTRES (SEQ ID №2) , HVR-L3, comprising the sequence QQYYAYPWT (SEQ ID №3), HVR-H1, the sequence comprising GYTFTSYWLH (SEQ ID №4), HVR-H2, having the sequence GMIDPSNSDTRFNPNFKD (SEQ ID №5) and HVR-H3, comprising the sequence ATYRSYVTPLDY (SEQ ID №6), and wherein the anti-c-met comprises one arm and comprises an antigen-binding Fc-region, wherein Fc-region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are complex (b) a histidine buffer at pH 5,0-5,4 (c) a saccharide and (d) polysorbate, wherein the polysorbate is present in an amount greater than 0.02% w / ob.2. Pharmaceutical preparation according to claim 1, wherein the antibody against c-met comprises (a) a heavy chain variable domain comprising the sequence:. EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWLHWVRQAPGKGLEWVGMIDPS NSDTRFNPNFKDRFTISADTSKNTAYLQMNSLRAEDTAVYYCATYRSYVTPLDY WGQGTLVTVSS (SEQ ID №19) and (b) light chain variable domain comprising the sequence: DIQMTQSPSSLSASVGDRVTITCKSSQSLLYTSSQKNYLAWYQQKPGKAPKLLIY WASTRESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYAYPWTFGQGTKVEIKR (SEQ ID №20) .3. Pharmaceutical preparation according to claim. 2, wherein the first and second Fc polypeptides to form Fc-region that increases stability of said antibody fragment compared to a molecule of Fab, comprising said antigen-binding plecho.4. A pharmaceutical preparation according to any one of claims. 1-3, wherein the antibody against c-met comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID №19, CH1 sequence and the first Fc polypeptide and (b) a second polypeptide comprising the amino acid sequence of SEQ ID №20 and sequence CL1.5 . druggist1. Фармацевтический препарат, содержащий:(a) антитело против c-met, где антитело против c-met содержит HVR-L1, содержащую пос
